In other recent news, Novavax is awaiting approval from the U.S. Food and Drug Administration (FDA) to release its COVID-19 vaccine, designed to target the JN.1 variant. The company has faced challenges in bringing its protein-based COVID-19 vaccine to market. However, a recent licensing agreement with Sanofi (NASDAQ: SNY ), valued at a minimum of $1.2 billion, has provided a significant boost. Despite this, Novavax forecasts revenues ranging from $400 million to $600 million for 2024, a notable decrease from 2023's $983.7 million.